Guido Marcucci Selected Research

Acute Myeloid Leukemia (Acute Myelogenous Leukemia)

3/2022	Synergy of Venetoclax and 8-Chloro-Adenosine in AML: The Interplay of rRNA Inhibition and Fatty Acid Metabolism.
1/2022	Dynamic patterns of microRNA expression during acute myeloid leukemia state-transition.
1/2022	Total Marrow and Lymphoid Irradiation with Post-Transplantation Cyclophosphamide for Patients with AML in Remission.
1/2022	MicroRNA networks in FLT3-ITD acute myeloid leukemia.
12/2021	Ex vivo isolation, expansion and bioengineering of CCR7+CD95-/or CD62L+CD45RA+ tumor infiltrating lymphocytes from acute myeloid leukemia patients' bone marrow.
1/2021	Cytoplasmic DROSHA and non-canonical mechanisms of MiR-155 biogenesis in FLT3-ITD acute myeloid leukemia.
1/2021	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.
1/2021	Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine.
1/2021	Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure.
1/2021	Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351).

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Guido Marcucci Research Topics

Disease

150	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 03/2022 - 09/2003
85	Neoplasms (Cancer) 01/2022 - 05/2005
76	Leukemia 06/2022 - 02/2002
23	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 02/2022 - 07/2007
12	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2022 - 07/2008
12	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2022 - 04/2003
12	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2022 - 05/2005
12	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 03/2014 - 07/2003
11	Hematologic Neoplasms (Hematological Malignancy) 12/2021 - 01/2006
11	Chromosome Aberrations (Chromosome Abnormalities) 01/2021 - 04/2003
9	Philadelphia Chromosome 02/2017 - 04/2003
8	Blast Crisis (Blast Phase) 01/2022 - 11/2005
7	Multiple Myeloma 01/2021 - 06/2008
7	Lymphoma (Lymphomas) 01/2021 - 05/2006
7	B-Cell Lymphoma (Lymphoma, B Cell) 01/2020 - 05/2006
6	Breast Neoplasms (Breast Cancer) 01/2020 - 08/2009
6	Carcinogenesis 01/2020 - 10/2007
5	Infections 11/2009 - 09/2004
4	Residual Neoplasm 02/2022 - 12/2016
4	Primary Myelofibrosis (Myelosclerosis) 01/2022 - 01/2019
4	Inflammation (Inflammations) 01/2020 - 09/2007
4	Myeloid Leukemia (Leukemia, Myelocytic) 01/2019 - 04/2005
3	Cytokine Release Syndrome 01/2022 - 01/2020
3	Colonic Neoplasms (Colon Cancer) 10/2020 - 11/2011
3	Large Granular Lymphocytic Leukemia 11/2012 - 05/2009
3	Carcinoma (Carcinomatosis) 01/2010 - 04/2005
2	Pathologic Complete Response 01/2022 - 01/2020
2	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 10/2021 - 01/2020

Drug/Important Bio-Agent (IBA)

38	MicroRNAs (MicroRNA)IBA 01/2022 - 10/2007
29	Proteins (Proteins, Gene)FDA Link 01/2022 - 07/2003
17	venetoclaxIBA 03/2022 - 03/2014
17	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2021 - 01/2003
16	Decitabine FDA Link 01/2020 - 01/2006
14	Biological ProductsIBA 01/2020 - 02/2002
13	Pharmaceutical PreparationsIBA 06/2022 - 02/2008
11	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 02/2005
10	Messenger RNA (mRNA)IBA 03/2022 - 01/2009
10	RNA (Ribonucleic Acid)IBA 01/2021 - 06/2009
10	Core Binding Factors (Core-Binding Factor)IBA 01/2021 - 09/2003
10	Phosphotransferases (Kinase)IBA 01/2019 - 11/2005
10	oblimersen (G3139)IBA 01/2010 - 01/2003
9	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 05/2006
8	Histones (Histone)IBA 11/2019 - 07/2003
8	Tyrosine Kinase InhibitorsIBA 02/2019 - 10/2013
8	MethyltransferasesIBA 01/2018 - 02/2005
7	Ribonucleotide Reductases (Ribonucleotide Reductase)IBA 01/2022 - 06/2008
7	fludarabineIBA 01/2022 - 01/2003
7	OligonucleotidesIBA 01/2020 - 06/2009
7	Histone Deacetylase InhibitorsIBA 01/2016 - 01/2004
7	Bortezomib (Velcade)FDA Link 01/2016 - 05/2006
7	Antisense OligonucleotidesIBA 06/2015 - 01/2003
7	Histone Deacetylases (Histone Deacetylase)IBA 12/2012 - 07/2003
7	DepsipeptidesIBA 12/2006 - 06/2003
6	Lenalidomide (CC 5013)FDA Link 12/2020 - 12/2008
6	mouse MIRN29 microRNAIBA 01/2019 - 06/2009
6	Transcription Factors (Transcription Factor)IBA 12/2016 - 05/2012
6	GTI2040IBA 06/2015 - 06/2006
5	blinatumomabIBA 02/2022 - 09/2017
5	Tacrolimus (Prograf)FDA LinkGeneric 01/2022 - 01/2016
5	CytokinesIBA 10/2021 - 02/2002
5	Protein Isoforms (Isoforms)IBA 01/2019 - 01/2013
4	Sirolimus (Rapamycin)FDA Link 01/2022 - 01/2016
4	Melphalan (Alkeran)FDA LinkGeneric 01/2022 - 01/2018
4	6-methyladenineIBA 01/2021 - 01/2018
4	midostaurinIBA 01/2021 - 01/2016
4	EnzymesIBA 12/2020 - 10/2007
4	Etoposide (VP 16)FDA LinkGeneric 01/2020 - 12/2006
4	Azacitidine (5 Azacytidine)FDA Link 01/2019 - 05/2005
4	romidepsin (FK228)FDA Link 07/2005 - 06/2003
3	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 01/2022 - 03/2013
3	triphosphoric acid (triphosphate)IBA 01/2022 - 06/2009
3	Daunorubicin (Cerubidine)FDA LinkGeneric 01/2021 - 01/2013
3	daratumumabIBA 01/2021 - 01/2018
3	fms-Like Tyrosine Kinase 3IBA 10/2020 - 01/2017
3	N-methyladenosineIBA 01/2020 - 11/2018
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2016 - 05/2008
3	Interleukin-15 (Interleukin 15)IBA 01/2016 - 04/2011
3	NucleophosminIBA 04/2014 - 05/2008
3	Imatinib Mesylate (Gleevec)FDA Link 01/2014 - 04/2003
3	Transferrin (beta 2 Transferrin)IBA 05/2013 - 06/2009
3	Liposomes (Liposome)IBA 01/2013 - 01/2010
3	Biomarkers (Surrogate Marker)IBA 11/2012 - 01/2005
3	Folic Acid (Vitamin M)FDA LinkGeneric 12/2010 - 03/2006
3	alvocidib (flavopiridol)IBA 12/2010 - 01/2009
3	Therapeutic UsesIBA 02/2010 - 06/2008
3	OligodeoxyribonucleotidesIBA 02/2010 - 04/2008
3	Antisense OligodeoxyribonucleotidesIBA 11/2009 - 03/2006
3	NF-kappa B (NF-kB)IBA 08/2009 - 02/2008
2	ibrutinibIBA 01/2022 - 11/2016
2	ruxolitinibIBA 01/2022 - 01/2021

Therapy/Procedure

58	Therapeutics 02/2022 - 02/2002
28	Drug Therapy (Chemotherapy) 10/2021 - 01/2003
23	Cell Transplantation 01/2022 - 01/2006
8	Transplantation 01/2022 - 07/2008
7	Homologous Transplantation 01/2022 - 11/2009
6	Stem Cell Transplantation 12/2017 - 01/2006
5	Hematopoietic Stem Cell Transplantation 12/2019 - 01/2016
4	Salvage Therapy 01/2021 - 08/2005
4	Consolidation Chemotherapy 01/2020 - 06/2005
2	Lymphatic Irradiation 01/2022 - 04/2017